Morphometric and functional changes of salivary gland dysfunction after radioactive iodine ablation in a murine model by �엫�옱�뿴
THYROID RADIOLOGY AND NUCLEAR MEDICINE
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Background: Ablation of the thyroid tissue using radioactive iodine (RAI) after the surgical removal of well-
differentiated thyroid cancer can induce radiation-related salivary gland (SG) dysfunction. However, in vivo
changes of SGs after RAI administration in appropriate animal models are not well described in the literature.
This study was undertaken to document morphometric and functional changes during the 12 months after RAI
administration in a murine model of RAI-induced SG dysfunction.
Methods: Four-week-old female C57BL/6 mice (n = 60) were divided into an RAI-treated group (n= 30) that
received RAI orally (0.01 mCi/g body weight) and an unexposed control group (n= 30). Mice in both groups
were divided into five subgroups (n = 6 per subgroup) and euthanized at 1, 2, 3, 6, and 12 months post-RAI
administration. Salivary flow rates and salivary lag times were measured at 1, 2, 3, 6, and 12 months after
RAI administration. Morphological and histological examinations and terminal deoxynucleotidyl transferase
dUTP nick end labeling assays were performed. In addition, changes in salivary 99mTc pertechnetate uptake and
excretion were observed by single-photon emission computed tomography.
Results: In RAI-treated mice, the SGs were significantly lighter than those of unexposed controls at all study time
points. Lag times to salivation in the RAI-treated group were greater than in the unexposed controls, but mean
salivary flow rates were lower. Histologic examinations of SGs in the RAI group showed pale cytoplasm,
atypical ductal configuration, septal widening, cytoplasmic vacuolization with pleomorphism, lymphocyte in-
filtration, and increased fibrosis. Furthermore, more apoptotic cells were observed in acini and ducts in the RAI
group. In addition, patterns of 99mTc pertechnetate uptake and excretion in the RAI group were quite different
from those observed in controls at 1 and 12 months post-RAI.
Conclusion: Various histological alterations were observed in mice exposed to RAI, that is, an increase in
apoptotic acini and ductal cells and functional SG deterioration. The murine model of RAI-induced SG dys-
function used in the present study appears to be applicable to preclinical research on RAI-induced sialadenitis in
patients with well-differentiated thyroid cancer.
Introduction
Radioactive iodine (RAI) ablation is performed to de-tect and remove remnant thyroid tissue in patients who
have undergone total thyroidectomy for well-differentiated
thyroid cancer. After RAI therapy, patients often complain of
painful swelling of salivary glands (SGs), xerostomia, taste al-
terations, or oral infections (1–4). Furthermore, RAI therapy
increases the risks of caries and tooth extraction (5), and SG
dysfunction induced by RAI impairs long-term oral health and
quality of life.
However, the in vivo SG changes induced by RAI admin-
istration in an appropriate animal model have not been well
described in the literature. In this study, we investigated
morphometric and functional changes that occurred during
the 12 months after RAI administration in a murine model of
RAI-induced SG dysfunction. During the study, wemeasured
(i) changes in bodyweight, (ii) changes in SGweights, and (iii)
salivary lag times (times from pilocarpine administration
until commencement of salivary flow) and salivary flow
rates (SFRs), and performed (iv) histopathologic examina-
tions, (v) terminal deoxynucleotidyl transferase dUDP nick
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end labeling (TUNEL) assays to detect apoptosis, and (vi)
single-photon emission computed tomography (SPECT) to
evaluate changes in 99mTc pertechnetate salivary uptake and
excretion rates.
Materials and Methods
Animal studies
Sixty female, 4-week-old, C57BL/6 mice weighing 18–22 g
were obtained from the Animal House Facility, National
Cancer Research Center, and maintained under temperature-
and light-controlled conditions in an animal facility with free
access to water and a standard mouse diet. Animal studies
were performed in compliance with the National Cancer
Research Center Institutional Animal Ethics Committee’s
guidelines.
RAI was not administered to group A (unexposed control
group, n = 30). Group B (RAI-treated group, n = 30) received
RAI intraorally (0.01 mCi/g body weight, 131I; New Korea
Industrial). RAI administrationwas defined to occur on day 0.
Both groups were then divided into five subgroups (n = 6 per
subgroup) and euthanized at 1, 2, 3, 6, and 12 months post-
treatment, respectively.
Measurements of mouse body weights, SG weights,
salivary lag times, and SFRs
Mice were weighed, and administered ketamine (100mg/
kg) and xylazine (5mg/kg) in sterile water intraperitoneally
(i.p.). Pilocarpine (2mg/kg body weight; i.p.) was then ad-
ministered. Saliva was collected for 5 minutes after pilocar-
pine administration using a specifically designed suction
device and placed in a preweighed 0.75mL Eppendorf tube.
SFR (lL/min) was defined as the total saliva weight (mg)
divided by the collection time (min) (saliva was assumed to
have a specific gravity of 1mg/mL). Salivary lag time was
defined as time from stimulation to the commencement of
saliva secretion. After saliva collection and euthanasia, sub-
maxillary glands were harvested and surrounding fat and
connective tissues were removed. Both submaxillary glands
were weighed.
Morphological analysis of tissues and TUNEL assay
SGs were immediately placed in 4% paraformaldehyde at
room temperature, processed, embedded in paraffin, sec-
tioned at 4 lm, and stained with hematoxylin and eosin and
Masson’s Trichrome.
Apoptosis in SG tissues was quantified by the TUNEL
assay using an ApopTag Plus In Situ Apoptosis Kit (Chemicon
Int.) at 2, 6, and 12 months post-RAI administration. TUNEL-
positive cells were detected at 400· , and two blinded exam-
iners independently counted the numbers of apoptotic cells in
three random fields per tissue section.
SPECT protocol
Technetium pertechnetate (55.5MBq, [99mTc] TcO4
- ; New
Korea Industrial) was administered i.p. to the anesthetized
mice. The mice were maintained in an unconscious state
during the entire imaging protocol using isoflurane (2 vol.% in
air). Whole-body SPECT imaging was started immediately
after [99mTc]TcO4
- injection and was repeated every 5–100
minutes (NanoSPECT; Bioscan). Overall, 21 images were ob-
tained per mouse. Pilocarpine (2mg/kg body weight; i.p.)
was administered at 60minutes post-SPECT. Eachmousewas
imaged at 1 and 12 months post-RAI.
Whole-body SPECT protocol
Whole-body SPECT images of each mouse were obtained
using a large field-of-view rotating gamma camera equipped
with four multipinhole collimators (Fig. 1A, B). The acquisi-
tion parameters used were as follows: 24 projections over
360, a circular orbit, and a total acquisition time of 6 minutes
(4 seconds per projection). Tomographic images were re-
constructed using an iterative reconstruction algorithm) (6,7).
SPECT image analysis
SPECT images were reviewed and quantified using In Vivo
Scope (Bioscan) and Osirix (The Osirix Foundation) imaging
software. Regions of interest were drawn manually around
FIG. 1. Planar whole-body images of (A) an unexposed
control mouse and (B) an RAI-administered mouse, and neck
transaxial planar images of (C) an unexposed control mouse
and (D) an RAI-treated mouse. Whole-body imaging was
performed in anterior view using a pinhole 10 cm removed
from target mice. Thyroid tissue was not imaged by neck
transaxial planar imaging in RAI-administered mice because
of the ablative effects of treatment after 1 month. RAI, ra-
dioactive iodine.
1446 CHOI ET AL.
the thyroid and SGs on images obtained 60 minutes post-
contrast administration that best depicted thyroid and SG
contours. Regions of interest of each lesion were combined
into a volume of interest (VOI), and VOIs were copied and
pasted onto SPECT images, except for images obtained at 60
minutes post-contrast administration. In addition, all VOIs
were corrected to ensure that they did not contain counts from
neighboring tissues, such as bone (Fig. 2C, D). The radioac-
tivity values of all voxels in VOIs were measured and cor-
rected for activity decay post-treatment. We used maximal
normalized radioactivity in VOIs as representative values to
minimize partial-volume effects. No thyroid tissue was im-
aged in the RAI-treatedmice.We attribute this to RAI ablation
of thyroid tissues.
Statistical analysis
Data were analyzed using GraphPad Prism 5 package
(GraphPad Software Inc.). The significances of differences
between groups were determined using the Student’s t-test
and two-way analysis of variance. Differences were accepted
to be statistically significant at p < 0.05. All results are ex-
pressed as means – standard deviations.
Results
Changes in body and SG weights
At baseline, no significant weight difference was observed
between the RAI-treated group and the unexposed control
group ( p=0.54). However, at 1, 2, and 12 months post-RAI
administration, mice in the RAI-treated group weighed signif-
icantly less than mice in the unexposed control group ( p< 0.01,
p=0.04, and p= 0.03, respectively) (Fig. 2A). SGs of RAI-treated
mice also weighed significantly less than those of unexposed
control mice at 1, 2, 3, and 6 months ( p= 0.04, p< 0.01, p= 0.02,
and p= 0.01, respectively) (Fig. 2B). Reductions in SG weight
were greater than reductions in body weight in RAI-treated
mice than in unexposed controlmice at 1, 2, 3, 6, and 12months,
and differences were statistically significant at 2 and 3 months
( p<0.001 and p<0.05, respectively).
Salivary lag times and SFRs
No significant intergroup difference was observed between
salivary lag times at 1 ( p= 0.44) or 2 months ( p = 0.79), but
mean lag times in the RAI-treated group were greater than
those in the unexposed control group between 3 and 12
FIG. 2. (A) Comparison of mouse weights. Mice in the RAI-treated group weighed less than mice in the unexposed control
group at 1 month post-treatment, and significantly less than mice in the unexposed control group at 1, 2, and 12 months post-
treatment ( p < 0.001). (B) Comparison of SG weights. SGs weighed less in the RAI-treated group than in the unexposed
control group from 1 to 12 months post-treatment, and these differences were significant at 1, 2, 3, and 6 months ( p< 0.001).
(C) Comparison of salivary lag times. No significant intergroup difference in lag times was observed at 1 or 2 months post-
treatment. However, mean lag times in the RAI-treated group were significantly greater from 3 to 12 months ( p< 0.001). (D)
Comparison of SFRs. No significant intergroup difference in SFRs was observed at 1 or 2 months post-treatment, but the
mean SFRs in the RAI-treated group were significantly smaller than those in the unexposed control group at 3–12 months
post-treatment ( p < 0.001). (A–D) Dots and error bars denote means – standard deviations; x-axis denotes months (M); as-
terisks indicate statistically significant points (NL, normal unexposed control group; RAI, RAI-treated group). SG, salivary
gland; SFRs, salivary flow rates.
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months ( p< 0.01, p= 0.04, and p < 0.01, respectively) (Fig. 2C).
In addition, no significant difference between mean SFR val-
ues was observed at 1 ( p = 0.91) or 2 months ( p = 0.97). Mean
SFR in the RAI-treated group was less than that in the unex-
posed control group at 3–12 months ( p< 0.01, p = 0.04, and
p < 0.01, respectively) (Fig. 2D).
Evaluation of histological changes and apoptosis
No significant pathologic changes were observed in RAI-
treated SGs at 1 or 2 months. RAI-treated SGs exhibited pale
cytoplasm (Fig. 3B), atypical ductal configuration (Fig. 3C),
septal widening (Fig. 3D), and lymphocyte infiltration (Fig.
3E) at 6 months, and cytoplasmic vacuolization with pleo-
morphism (Fig. 3F) at 3 months as compared with unexposed
SGs (Fig. 3A). Furthermore, Masson’s Trichrome staining of
RAI-treated SGs revealed higher levels of fibrosis (Fig. 3G, H).
TUNEL assays showed that the number of apoptotic acinar
cells was significantly higher in the RAI-treated group at 2, 6,
and 12 months ( p = 0.04, p= 0.05, and p < 0.01, respectively)
(Fig. 4A). Similarly, numbers of apoptotic ductal cells were
significantly higher in the RAI-treated group at 2 and 12
months ( p< 0.01 and p < 0.01, respectively) (Fig. 4B).
SPECT: Dynamics of 99mTc pertechnetate uptake
and excretion at 1 and 12 months post-treatment
The rate of 99mTc pertechnetate uptake in unexposed con-
trols was greater than that in RAI-treated mice, and the 99mTc
pertechnetate excretion amount was markedly lower in RAI-
treated mice at 1 month post-RAI administration (Fig. 5A).
The rate of 99mTc pertechnetate uptake in RAI-treated mice
was lower than that in unexposed control mice, but the
amount of 99mTc pertechnetate excretion was similar in the
two groups at 12 months post-RAI (Fig. 5B).
Discussion
In recent years, RAI therapy after total thyroidectomy has
played an important role in the treatment of patients with
well-differentiated thyroid cancer. Ideally, this treatment
should ablate residual tumor cells in the neck and distant
metastases, but not affect surrounding healthy tissues (8).
However, RAI affects many nonthyroidal tissues, such as SGs,
lacrimal glands, gastric mucosa, lactating mammary glands,
placenta, thymus, lung, and bone marrow (9,10), because all
these tissues express the sodium iodide symporter (NIS). NIS
is an integral plasma membrane glycoprotein that mediates
the active transport of iodide ions into thyroid follicular cells
(11–13) and thus plays a major role in RAI uptake. As a result,
RAI can accumulate in SG tissues because of the action of
native NIS (14,15).
RAI-induced SG dysfunction, which may be transient or
permanent, impairs quality of life (5). Furthermore, because
patients with differentiated thyroid cancer have a good
prognosis, it is critical to minimize the side effects of RAI
therapy; for this reason, the protection of SGs after RAI ther-
apy has become an important issue.
FIG. 3. Histological analysis of representative samples. Histological analysis of normal SGs (submaxillary glands) revealed
the expected lobular structure with densely packed acini and a well-developed excretory duct system. (A) An unexposed
control at 12 months; (B) pale cytoplasm in an RAI-administered mouse at 12 months; (C) an atypical ductal configuration in
an RAI-administered mouse at 12 months; (D) septal widening in an RAI-administered mouse at 12 months; (E) lymphocytic
infiltration in an RAI-administered mouse at 12 months; (F) vacuolization with pleomorphism in an RAI-administered mouse
at 3 months; (G) an unexposed control at 12 months; (H) increased fibrosis in an RAI-administered mouse at 12 months. (A–F)
were stained with hematoxylin and eosin, and (G, H) were stained with Masson’s Trichrome (scale bar = 100lm).
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In the present study, we performed histopathologic and
functional examinations using a murine model of SG dys-
function induced by RAI, and observed both histological
and functional changes. RAI-treated mice were lighter than
unexposed control mice from 1 to 12 months post-RAI ad-
ministration, which we attribute to damaged oral health and
nutritional insufficiency after RAI exposure. However, it is
possible that weight loss was caused by hypothyroidism after
RAI administration, as results on this topic are discrepant
among species (16–19). The weights of SGs of RAI-treated
mice were less than those of unexposed control mice from 1 to
12 months, possibly indicating progressive atrophy.
No significant differences in salivary lag times or SFRswere
observed between the two groups at 1 or 2 months post-
treatment, but significant differences were found at 3 months,
which suggests that 3 months is the minimum time required
to observe SG dysfunction objectively by flow testing in our
murine model.
Histological changes in SGs after RAI administration were
also examined. RAI-treated SGs revealed nonspecific mani-
festations of cellular injury combined with acinar loss and
disorganization, and in some animals, glandular duct en-
largement and marked lipomatosis were observed (4,20–22).
Furthermore, SGs inRAI-treatedmice showedpale cytoplasm,
atypical ductal configuration, septal widening, lymphocyte
infiltration, cytoplasmic vacuolization with pleomorphism,
and increasing fibrosis in tissues.
Apoptosis is considered a possible mechanism of SG
damage induced by RAI (20). In the present study, TUNEL
assays revealed more apoptotic cells in both acini and ducts in
RAI-treated mice, indicating that ductal and acinar cells were
damaged by RAI. Nevertheless, further investigation of the
mechanisms responsible, including the downstream path-
way, for the RAI-induced apoptosis of SG epithelial cells is
required.
Salivary scintigraphy is a well-established technique for
evaluating salivary function and, in a previous study, con-
firmed the presence of SG damage by RAI in rabbits (22).
However, scintigraphy has not been used in mice because its
resolution is too poor to depict organs capable of accumu-
lating iodide. Accordingly, a tomographic technique, such as
SPECT, is needed to achieve the level of spatial resolution
required (23).
In the present study, we investigated the spatial distribu-
tions of the uptakes and excretions of 99mTc pertechnetate
from SGs. The rate of 99mTc pertechnetate uptake in the RAI-
treated group was found to be lower than that in the control
group, and the amount of 99mTc pertechnetate excreted was
markedly lower in the RAI group at 1 month post-treatment.
At 12 months, the rate of 99mTc pertechnetate uptake in the
RAI group was lower than that in the control group, but
the amounts of 99mTc pertechnetate excretion were similar
in the two groups. These results support the view that RAI
causes damage to SG acinar and ductal cells at 1 month after
treatment, and that at 12 months, acini cell damage persists,
whereas ductal cell damage improves with time. This finding
also demonstrates that SPECT provides an excellent means of
evaluating salivary function in small animal models.
In this study, we performed morphohistometric and func-
tional evaluations of RAI-induced SG dysfunction over 12
months post-RAI treatment using an in vivomurinemodel. To
the best of our knowledge, this is the first study to describe SG
damage in vivo over the long-term. However, this study has
some limitations that warrant consideration. First, an RAI
dose of 0.01 mCi/g bodyweight was administered based on a
review of related animal studies (0.004–0.0216 mCi/g body
weight) (20,24–26). According to our preliminary study, this
dose appeared to be sufficient to damage SGs without com-
promising general health. Nevertheless, additional studies are
required to investigate the RAI dose–response relationship,
and an appropriate preclinical animal model should be es-
tablished. Second, our histological study was limited to sub-
maxillary glands because parotid glands are too small to
monitor tissue acquisition in the mouse. Third, the most dif-
ficult aspect of this study was to manage RAI. Although RAI
emits low doses of radiation, examiners can be easily exposed
FIG. 4. Quantitative analysis by TUNEL assay. The analysis shows that the numbers of apoptotic cells were greater in the
RAI-treated group than in unexposed controls at 2, 6, and 12 months post-treatment. (A) The numbers of TUNEL-positive
cells per field in acinar cells ( p< 0.001), and (B) the numbers of TUNEL-positive cells per field in ductal cells ( p < 0.001). The
dots and error bars denote means and standard deviations, respectively. The x-axis denotes months (M); the y-axis, numbers
of apoptotic cells per field; and the asterisks, significant points (NL, normal unexposed control group; RAI, RAI-treated
group). TUNEL, terminal deoxynucleotidyl transferase dUDP nick end labeling.
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to the radioactivity. To avoid direct exposure to RAI, we could
not examine the mice contaminated by RAI within 1 month.
Because RAI has a half-life of about 8 days, the remaining
activity of RAI decreases to less than 12.5% of the initial
amount after 1 month. Therefore, all experiments were con-
ducted 1month after treatment at a time point when radiation
was minimal.
In conclusion, various patterns of alterations were ob-
served in RAI-treated mice, that is, body weight loss, SG
weight loss, increased salivary lag time, and reduced SFR.
FIG. 5. Dynamics of 99mTc pertechnetate uptake and excretion at (A) 1 month and (B) 12 months post-treatment. SG
dysfunction in the RAI-administered mice was caused by impaired uptake and marked impairment of excretion at 1 month
( p< 0.001). SG dysfunction in RAI-administered mice was caused by impaired uptake at 12 months ( p < 0.001). Arrows
indicate the time of pilocarpine injection. Dots and error bars denote means and standard deviations, respectively. The x-axis
denotes time (minutes); the y-axis, percentages of injected activity; and the asterisks, significant points (NL, normal unex-
posed control group; RAI, RAI-treated group).
1450 CHOI ET AL.
Furthermore, histological changes, including increased apo-
ptosis, and salivary dysfunction by SPECT were observed in
RAI-treated mice. We suggest that studies on the mechanism
and treatment of SG damage induced by RAI should be per-
formed using the described murine experimental model, be-
cause it appears to be appropriate for investigations of SG
functional recovery after RAI administration.
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